Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

Time to assess the situation again. Looks like the stock have hit the bottom and bounced a bit on rumor but doesn't looks like it's going to go much lower. The current price is basically pricing in complete Rexista failure because most believe FDA isn't likely to approve when the panel voted it down.

Risk factor involves FDA decisions. Date set in September so worst case scenario FDA rejects Rexista. However unlikely that might be it's a factor to consider. But, I have said above this is priced in.

Plus side is that we have projected Q3 earnings to be positive as well as into the year end which won't report until early 2018.

First foundation advisors involvement is a good sign. You could look at that as a partnership of some sort. 481k holding isn't something too exciting but it's a foot in the company. As we've been saying Odidi is a scientist. He may have business degree but that's not what he does best. First foundation advisors is likely a consultant Odidi bring on board to help him through tough times.

As long as Odidi don't dilute at the worst time possible we should see a recovery into Q3 reporting time. Potentially Rexista news may really swing things a bit but long term the share price should be higher than current level.